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OBJECTIVES: To examine the prevalence of Biologically Based Therapies (BBTs) use 
and assessment of Health Related Quality of Life (HRQoL) in a group of cancer 
patients. METHODS: The study was undertaken with 393 cancer patients at the 
oncology wards of Penang General Hospital, Malaysia. The health related quality of 
life was assessed by using European Organization for Research and Treatment of 
Cancer Quality of Life Questionnaire (EORTC QLQ-C30). RESULTS: Out of 393 
participants, 184 (46.1%) reported to use different types of Complementary and 
Alternative Medicines (CAM). Among the CAM users, 134 (72.8%) reported using 
BBTs and thus labelled as BBTs users and vice versa. Nutritional supplements such 
as vitamins, minerals, enzymes (n=139) and special diet such as herbs, animal 
products, juices (n=74) were the common type of BBTs used by patients. More than 
half of the participants were not sure of their monthly expenditures on BBTs. 
However, 26.3% reported to spend an average of 101-500Malaysian Ringgit (MYR) 
per month on these therapies. Friends and family members were the most 
common source of BBTs recommendations (75.5%). BBTs use was disclosed to the 
doctors by 42.1% of the participants. BBTs users reported better HRQoL compare to 
non BBTs users. On functional scale significant difference was observed in role 
(p=0.01) and emotional (p=0.04) scores between BBTs users and non-users. On 
symptoms scale fatigue (p=0.006), nausea &vomiting (p<0.001), pain (p=0.04), 
insomnia (p=0.01) and appetite loss (p<0.001) were significantly different among 
BBTs users and non-users. No significant difference was found in Global health 
status/quality of life score between BBTs users and non-users (p=0.85). 
CONCLUSIONS: The use of biologically based therapies is common among cancer 
patients in Malaysia. HRQoL assessment reveals better quality of life of BBTs users 
thus further research is required to evaluate the potential role of BBTs in cancer 
care.  
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OBJECTIVES: To review European Medicine Agency approvals in oncology for 
2006-2012 to determine commonly used primary endpoints and endpoints based 
on patient reported outcomes (PROs). METHODS: The initial identification of 
oncology approvals was conducted in PROLabels (2006-2012). This was 
supplemented with a review of European Assessment Reports, Summary of 
Product Characteristics, Procedural Steps, Summary of the European Public 
Assessment Report and Scientific Discussion documents. RESULTS: There were 8 
approvals in neoplasms, 3 in anemia, 4 in pain, 1 in nausea and vomiting, 1 in 
paroxysmal hemoglobinuria. Primary endpoints for approval of oncology drugs 
included progression free survival (n=5), endpoints based on pain intensity (n=3), 
overall survival (n=2), hemoglobin stabilization/blood transfusion requirement 
(n=1), no emesis/no use of rescue medications (n=1), lesion clearance (n=1). PRO 
measure used included the BPI-SF, MPQ, FACIT-F, FACIT-An, FACT-L, EORTC-
QLQ-C30, Pain NRS, nausea VAS, TSQM, Trial Outcomes Index and an unreported 
measure. The type of PRO endpoints in the approved labeling included: Pain 
(n=7), HRQOL (n=6), fatigue (n=3), emetic episodes/use of rescue medications 
(n=1), treatment satisfaction (n=1). CONCLUSIONS: Manufacturers frequently 
supplement primary endpoints with supplemental PRO data. European approvals 
include labeling information that is often not permitted by the FDA such as 
improved HRQOL.  
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OBJECTIVES: Although Hispanics are the fastest growing ethnic group and 
cancer the second leading cause of death among Hispanics in the U.S., few 
studies have documented the impact of cancer diagnosis on the quality of life 
and caregiving experiences of Hispanic family caregivers. The aim of this study 
was to explore the influence of culture on the caregiving experiences and 
perceptions of QOL among Mexican-American (MA) family caregivers of adults 
with advanced cancer. METHODS: This qualitative descriptive study was 
conducted in the ambulatory care setting of an NCI-Comprehensive cancer care 
center in the United States. Twenty MA family caregivers of patients with 
advanced cancer participated in qualitative interviews. Thematic analysis of the 
interviews and the conceptual model of Quality of Life Well-being developed by 
Ferrell, Wisdom, and Wenzel (1989) were used to characterize the caregiving 
experience and the effects of caregiving on QOL of MA cancer family caregivers. 
RESULTS: In general, the caregiving experience and the meaning of QOL 
centered on spiritual or religious beliefs and practices, concern for providing the 
best home care, inclusion of extended family support, and the desire to fulfill 
cultural role and responsibility expectations. Overall, MA caregivers emphasized 
that their caregiving experience had more positive than negative outcomes. The 
caregiver’s overall QOL was primarily affected by the patient’s advanced disease, 
the consequences of the cancer treatment and its related side effects, and the 
patient’s emotional/psychological needs. Secondarily, the caregiver’s overall 
perception of quality of life was affected by their physical, social, emotional and 
spiritual needs. CONCLUSIONS: These findings provide insight into the cultural 
dimension inherent in the caregiving experience and perceptions of QOL of MA 
cancer family caregivers. It is imperative to recognize the influence of culture in 
developing culturally relevant interventions specifically designed to reduce the 
burden of cancer and improve overall caregiver QOL.  
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OBJECTIVES: Patient reported outcomes (PRO) are becoming useful tools for 
collecting and generating evidence for new medical products to show 
improvements in health-related quality of life (HRQoL). Castration-Resistant 
Prostate Cancer (CRPC) is a chronic disease with high importance for patient 
HRQoL. The objective of this study was to review, analyze, and understand 
trends in the PRO instruments used in patients with CRPC. METHODS: A 
systematic literature search for CRPC randomized controlled trials (RCTs) with 
PROs endpoints was undertaken for the databases Pubmed, Embase, Biosis, 
Google Scholar, and Cochrane. Data was collected for the study size, 
interventions, year, PRO instrument, and results for PROs. Analysis was 
conducted to identify trends in commonly used PRO instruments and categorize 
results as positive, neutral or negative. RESULTS: Ten RCTs with a total of 5797 
patients were identified. In these studies there were 13 different PROs 
instruments were identified that were FACT-P, FACT-G, BPI-SF, EQC30, EQPR25, 
FLIC, SDS, SUF, PDA, IPDA, PROSQOLI, SF-36, and QOLM-P14. The most 
commonly used instrument were FACT-P (used in 4,297 patients) and EQC-30 
(used in 1,091 patients). Six studies reported positive results with improvement 
in quality of life symptoms (QoL) versus comparator treatments. Fours studies 
reported results with deterioration in (QOL). Three studies reported 
improvement in pain scores. CONCLUSIONS: Patients with CRPC have relatively 
longer survival and hence QoL is an important consideration for these patients. 
PRO instruments such as FACT-P and EQC-30 have been commonly used to 
generate evidence to show which therapies improve patient QoL.  
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OBJECTIVES: Despite a shift towards consideration of pain as a focus of 
treatment rather than a symptom to be managed, the introduction of new 
products for pain has been detrimentally affected by reimbursement frameworks 
that are unlikely to support decisions that favour patient access. This situation 
exists despite public support for effective pain management, particularly within 
the palliative care setting. This study aims to identify the mechanisms that limit 
the available therapeutic options in pain management and to suggest potential 
alternative approaches to be considered. METHODS: The study involved 
interviews with 30 interviewees in the US, France, Germany and the UK, 
including national level HTA influencers, medical directors, influencers on 
hospital formularies and product use, palliative medicine consultants, 
anaesthesiologists and oncologists. Interviews focused on the challenges of 
securing a favourable reimbursement status and a commercially viable price in a 
pain indication, as well as the difference between treatment guidelines and 
clinical practice. The success (or not) of market access for 4 selected pain 
products was also assessed based upon a set of criteria set out in the poster. The 
organisational structures for delivery of pain services were also considered. 
RESULTS: New pain products struggle to secure uptake in both the US and EU. 
Countries adopting a model that attaches the achievable price level with the 
level of additional clinical benefit demonstrated (France, Germany) are reluctant 
to consider favourable assessment versus established cheap products. The 
absence of life extension and common existence of pain in late stage disease 
means countries adopting a cost-effectiveness model (UK) are methodologically 
unsuited to evaluation of such products. US payers are likely to place restrictive 
prior authorisation requirements on products while cheap options exist. 
CONCLUSIONS: Patient access to new pain therapies is significantly limited by 
reimbursement policy in the US and EU, including in instances where the 
product has a recognised clinical benefit.  
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OBJECTIVES: To explore the prevalence, diagnosis & treatment protocol of breast 
cancer in patients treated at Bahawalpur institute of nuclear medicine and 
oncology (BINO). METHODS: A retrospective study was carried out on the data 
from the treatment records of patients (n=300). Patient age, education status, 
involved breast, type & stage of disease at diagnosis, socioeconomic status of 
patients & metastasis in patients as well as the treatment protocols was 
evaluated. Statistical tools were applied for analysis. RESULTS: The mean age of 
patients was 48±15 & 92% patients were illiterate. Infiltrating ductal carcinoma 
(IDC) 96% was the most common type of breast cancer found in population and 
were mostly diagnosed at Grade 3 (69%). Most of the patient had carcinoma of 
